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Apheresis (AP) has been applied in the complex treatment of 
more than 60 diseases, but a benefical effect has been proven for 33 
of them (4). AP has an activating, immunomodulatory and detoxicat-
ing function (3). The best effect was achieved on diseases of immune 
and autoimmune genesis. One sole procedure is capable of removal 
of 80% of the circulating immune complexes (CIC) and 50% of the 
immunoglobulins (5). 
The present investigation aims at establishing the effect of AP 
application to the complex treatment of immune nephropathies, 
multiple myeloma, pruritus and polyneuropathy in patients on hemo­
dialysis, rheumatoid arthritis and some skin diseases. 
A total of 427 AP have been performed in the Department of Ne­
phrology and Heamodialysis during the period 1979-1991 (269 with 
the centrifugal method and 158 - plasmafiltrations) to 143 patients: 
39 with immune nephropathies, 34 with multiple myeloma and 34 on 
periodic haemodialysis (three with polyneuropathy, 20 with pruritus, 
and II with both complications), 5 patients with rheumatoid arthritis, 
16 with erythrocytaemia associated with respiratory failure, 9 pa­
tients with skin diseases, 4 with phalloid intoxication and two donor 
cytophereses (1,2). 
Two patients with homozygous form of familial hypercholestero­
lemia II А-type according to Fredericksen received 44 and 48 weekly 
LDL-aphereses, respectively. Plasmapheresis was initially per­
formed, whereupon the separated plasma was passed through col­
umns containing monoclonal antibodies against low density 
lipoproteins. 
AP was carried out in two different ways: with "Haemonetics M-
30" and with membrane plasmaseparator "Plasmaflux": 1150 up to 
2200 ml of plasma per procedure was being removed in the different 
groups in periods of 2-5 days. The removed plasma was substituted 
with saline and plasma infusions in approximately equal quantities. 
The effect of AP treatment was assessed through clinical and labor­
atory data: CIC, Paramecium test for plasma toxicity, phagocytic ac­
tivity, total serum proteins and specific tests for the different diseases 
(viscosity, histamine, specific antibodies, etc.). 
Of our cases, 83,7% of the patients with immune nephropathies 
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that had in time been treated with AP and immunosuppressions in 
combination went into a stage of remission, which is still going on 
52,7 months after. The immunosuppressive therapy was applied at 
lower dosage to nine patients. The treatment exerted no effect on pa­
tients with pre-end stage renal disease. 
A clinical remission of 8,1 months was achieved in 74,8% of the 
patients on periodic dialysis with pruritus after 3,4 APs on average, 
in correlation with lowering the level of serum histamine. Electro­
myographic and clinical improvement of polyneuropathy was regis­
tered in 64,8% of the treated 8,4 months after the application of 4,9 
aphereses on average. 
The application of a single procedure every 2-3 months in pa­
tients with myeloma multiplex lowers viscosity, improves microcircu­
lation and slows down the progression of myeloma nephropathy. The 
cytostatic therapy was reduced in eight patients. 
Statistically significant diminution of pathologically increased 
plasma viscosity, normalization of haematocrit and partial pressure 
of oxygen were noted after the second erythrocytopheresis in pa­
tients with chronic respiratory failure. 
The total plasma cholesterol was decreased with 50,49% on 
average with LDL-apheresis in the patients with familial hypercholes­
terolemia, and the treatment frequency had to be at last once a week 
for a good effect to be obtained. 
The results in patients with rheumatoid arthritis, phalloid intoxi­
cation and skin diseases were controversial. 
CIC level changed most significantly after AP in patients with im­
mune nephropathies and rheumatiod arthritis. 
The best improvement of macrophageal activity of polymorpho­
nuclear leukooytes was registered in patients on haemodialysis with 
immune nephropathies and rheumatoid arthritis. After 2-3 APs vis­
cosity was brought to normal in patients with respiratory failure and 
myeloma multiplex. A considerable decrease of plasma toxicity was 
achieved in patients on hemodialysis and phalloid intoxication. 
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